Bayer announced Nov. 21 that it will soon include safety study summaries of glyphosate on its dedicated transparency platform.
The company said this next step will mark the first anniversary of its Transparency Initiative, which was launched on Dec. 7, 2017.
“Our commitment to transparency remains core to our mission as we move forward as a combined company,” said Liam Condon, member of the Bayer AG board of management and president of the Crop Science Division. “We recognize that people around the world want more information around glyphosate, and we are eager to offer access to our glyphosate-related safety data on our dedicated transparency platform. This platform has set new standards of accountability and responsibility in the sector; we pledge to use it as a springboard to continue to share science-based information with the public.”
Bayer said its platform demonstrates how transparency regarding crop protection safety studies can help the company achieve its commitment to sound science and the safe use of its products while at the same time maintaining confidential business information.
In addition to the glyphosate study summaries, which will be made available on Dec. 7, 2018, access to the underlying safety study reports — owned by Bayer and submitted for the review that led to the European substance renewal decision in December — will be enabled next year.
Bayer is a global enterprise with core competencies in the life science fields of health care and agriculture. In fiscal 2017, the group employed around 99,800 people and had sales of 35.0 billion euros.